OLBH Offers Heart Failure Monitoring Solution

OLBH now offers patients a new miniaturized, wireless monitoring sensor to manage heart failure. The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.

The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery during a non-surgical procedure to directly measure pressure. Increased pulmonary artery pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers at OLBH allowing for personalized and proactive management to reduce the likelihood of hospitalization.

“We’re excited to have this innovative technology available to our patients because of its ability to improve outcomes for heart failure,” said OLBH Director of Cardiovascular Services Shelley J. Carrico, R.T. (R) (CV). “The monitor allows patients and our providers to get ahead of a potential issue before it develops into a problem.”

Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands. According to the American Heart Association, nearly six million Americans have heart failure and 900,000 new patients are diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death. The Centers for Disease Control and Prevention says that half of heart failure patients die within five years of diagnosis. 

The CardioMEMS sensor is designed to last the lifetime of the patient and doesn’t require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The CardioMEMS HF System allows patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized. 

Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. Heart failure is the leading cause of hospitalization for Americans over age 65. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. in 2012 was $31 billion and that number is expected to more than double by 2030.